Table of Contents Author Guidelines Submit a Manuscript
Advances in Urology
Volume 2009, Article ID 818965, 3 pages
http://dx.doi.org/10.1155/2009/818965
Review Article

The Impact of Diabetes Type 2 in the Pathogenesis of Benign Prostatic Hyperplasia: A Review

Urology Department, Tzaneion General Hospital, 2 Salepoula street, 18536 Piraeus, Greece

Received 7 March 2009; Accepted 13 October 2009

Academic Editor: Narmada Gupta

Copyright © 2009 K. Stamatiou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Lee, J. M. Kozlowski, and J. T. Grayhack, “Etiology of benign prostatic hyperplasia,” Urologic Clinics of North America, vol. 22, no. 2, pp. 237–246, 1995. View at Google Scholar · View at Scopus
  2. A. W. Partin, J. E. Oesterling, J. I. Epstein et al., “Influence of age and endocrine factors on the volume of benign prostatic hyperplasia,” Journal of Urology, vol. 145, no. 2, pp. 405–409, 1991. View at Google Scholar · View at Scopus
  3. N. M. Gades, D. J. Jacobson, C. J. Girman, R. O. Roberts, M. M. Lieber, and S. J. Jacobsen, “Prevalence of conditions potentially associated with lower urinary tract symptoms in men,” BJU International, vol. 95, no. 4, pp. 549–553, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. R. Defronzo and E. Ferrarini, “Insulin resistance. A multifaced syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and arteriosclerotic cardiovascular disease,” Diabetes Care, vol. 14, pp. 173–194, 1991. View at Google Scholar
  5. J. B. Bourke and J. P. Griffin, “Hypertension, diabetes mellitus, and blood groups in benign prostatic hypertrophy,” British Journal of Urology, vol. 38, no. 1, pp. 18–23, 1966. View at Google Scholar · View at Scopus
  6. J. Hammarsten, B. Högstedt, N. Holthuis, and D. Mellström, “Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia,” Prostate Cancer and Prostatic Diseases, vol. 1, no. 3, pp. 157–162, 1998. View at Google Scholar · View at Scopus
  7. M. R. Safarinejad, “Prevalence of benign prostatic hyperplasia in a population-based study in Iranian men 40 years old or older,” International Urology and Nephrology, vol. 40, no. 4, pp. 921–931, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. A. V. Sarma, J. P. Burke, D. J. Jacobson et al., “Associations between diabetes and clinical markers of benign prostatic hyperplasia among community-dwelling black and white men,” Diabetes Care, vol. 31, no. 3, pp. 476–482, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. S. A. Kaplan, A. E. Te, and J. G. Blaivas, “Urodynamic findings in patients with diabetic cystopathy,” Journal of Urology, vol. 153, no. 2, pp. 342–344, 1995. View at Publisher · View at Google Scholar · View at Scopus
  10. J. S. Brown, H. Wessells, M. B. Chancellor et al., “Urologic complications of diabetes,” Diabetes Care, vol. 28, no. 1, pp. 177–185, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Bozlu, E. Ulusoy, S. Cayan, E. Akbay, S. Görür, and E. A. Akbay, “A comparison of four different α1-blockers in benign prostatic hyperplasia patients with and without diabetes,” Scandinavian Journal of Urology and Nephrology, vol. 38, no. 5, pp. 391–395, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. M. C. Michel, L. Mehlburger, H. Schumacher, H.-U. Bressel, and M. Goepel, “Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia,” Journal of Urology, vol. 163, no. 6, pp. 1725–1729, 2000. View at Google Scholar · View at Scopus
  13. C. Ozden, O. L. Ozdal, G. Urgancioglu, H. Koyuncu, S. Gokkaya, and A. Memis, “The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia,” European Urology, vol. 51, no. 1, pp. 199–206, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. J. K. Parsons, J. Bergstrom, and E. Barrett-Connor, “Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men,” BJU International, vol. 101, no. 3, pp. 313–318, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. J. Hammarsten and B. Högstedt, “Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia,” Blood Pressure, vol. 8, no. 1, pp. 29–36, 1999. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Nandeesha, B. C. Koner, L. N. Dorairajan, and S. K. Sen, “Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia,” Clinica Chimica Acta, vol. 370, no. 1-2, pp. 89–93, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. R. J. Barnard, N. Kobayashi, and W. J. Aronson, “Effect of diet and exercise intervention on the growth of prostate epithelial cells,” Prostate Cancer and Prostatic Diseases, vol. 11, no. 4, pp. 362–366, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. S. Kasturi, S. Russell, and K. T. McVary, “Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia,” Current Urology Reports, vol. 7, no. 4, pp. 288–292, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. A. P. Berger, M. Deibl, E. J. Halpern et al., “Vascular damage induced by type 2 diabetes mellitus as a risk factor for benign prostatic hyperplasia,” Diabetologia, vol. 48, no. 4, pp. 784–789, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. A. De Bellis, P. Ghiandi, A. Comerci et al., “Epidermal growth factor, epidermal growth factor receptor, and transforming growth factor-α in human hyperplastic prostate tissue: expression and cellular localization,” The Journal of Clinical Endocrinology & Metabolism, vol. 81, no. 11, pp. 4148–4154, 1996. View at Publisher · View at Google Scholar · View at Scopus
  21. Z.-J. Wang, K. Ikeda, Y. Wada, H. E. Foster Jr., R. M. Weiss, and J. Latifpour, “Expression and localization of basic fibroblast growth factor in diabetic rat prostate,” BJU International, vol. 85, no. 7, pp. 945–952, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Monti, F. Di Silverio, R. Iraci et al., “Regional variations of insulin-like growth factor I (IGF-I), IGF-II, and receptor type I in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens,” The Journal of Clinical Endocrinology & Metabolism, vol. 86, no. 4, pp. 1700–1706, 2001. View at Google Scholar
  23. D. M. Peehl, P. Cohen, and R. G. Rosenfeld, “The insulin-like growth factor system in the prostate,” World Journal of Urology, vol. 13, no. 5, pp. 306–311, 1995. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Zhang, M. W. Hess, M. Thurnher et al., “Human prostatic smooth muscle cells in culture: estradiol enhances expression of smooth muscle cell-specific markers,” Prostate, vol. 30, no. 2, pp. 117–129, 1997. View at Google Scholar · View at Scopus
  25. C. W. Gregory, D. Kim, P. Ye et al., “Androgen receptor up-regulates insulin-like growth factor binding protein-5 (IGFBP-5) expression in a human prostate cancer xenograft,” Endocrinology, vol. 140, no. 5, pp. 2372–2381, 1999. View at Google Scholar